PAM
RARE icon

Princeton Alpha Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Princeton Alpha Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,382
Closed -$524K – 837
2016
Q3 		$524K Buy
7,382
+2,973
+67% +$190K 0.1% 314
2016
Q2 		$216K Buy
+4,409
New +$285K 0.04% 652

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Princeton Alpha Management's RARE Position: Q4 2016 in Review

Princeton Alpha Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2016, closing a stake of 7,382 shares — an estimated $524K sold.

Princeton Alpha Management first reported a position in RARE in Q2 2016 and held it in 2 quarters. The position peaked at $524K in Q3 2016. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

  • Princeton Alpha Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 7,382 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $524K.
  • Princeton Alpha Management first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and held it in 2 quarters.
  • Princeton Alpha Management's Ultragenyx Pharmaceutical position peaked at $524K in Q3 2016.
  • 174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on Princeton Alpha Management's 13F filing for Q4 2016, filed 10 Feb 2017.